BioNTech SE (BNTX) Depreciation & Amortization (CF) (2018 - 2026)
BioNTech SE (BNTX) posted Depreciation & Amortization (CF) of $15.7 million for Q1 2021, up 65.17% sequentially from $9.5 million in Q1 2020, and up 65.17% YoY from $9.5 million in Q1 2020.
Analysis
BioNTech SE (BNTX) Depreciation & Amortization (CF) (2018 - 2026) Analysis & Trends
BioNTech SE has reported Depreciation & Amortization (CF) for 4 years, with the latest figure at $15.7 million in Q1 2021.
- Quarterly Depreciation & Amortization (CF) rose 65.17% year-over-year to $15.7 million in Q1 2021, while the trailing twelve-month figure through Dec 2021 was $15.7 million (up 65.17% YoY) and the FY2020 annual result came in at $44236.9, up 16.53% from the prior year.
- Depreciation & Amortization (CF) climbed to $15.7 million in Q1 2021 per BNTX's latest filing, from $9.5 million in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $15.7 million in Q1 2021 and troughed at -$26.6 million in Q4 2019.
- A 4-year average of -$4.3 million and a median of -$3.1 million in 2018 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2019 and 2021: Depreciation & Amortization (CF) sank 69.8% in 2019, then surged 65.17% in 2021.
- Over 4 years, Depreciation & Amortization (CF) stood at -$15.7 million in 2018, then tumbled by 69.8% to -$26.6 million in 2019, then surged by 135.66% to $9.5 million in 2020, then soared by 65.17% to $15.7 million in 2021.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $15.7 million, $9.5 million, and -$26.6 million for Q1 2021, Q1 2020, and Q4 2019 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | BioNTech SE | 25.06 Bn | 11.41 Bn | 10.00 Mn | 309.30 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 309.30 Mn |
| Mar 31, 2026 | 142.01 Mn |
| Dec 31, 2025 | 191.83 Mn |
| Sep 30, 2025 | 145.20 Mn |
| Jun 30, 2025 | 57.73 Mn |
| Mar 31, 2025 | 45.02 Mn |
| Dec 31, 2024 | 176.75 Mn |
| Sep 30, 2024 | 48.76 Mn |
| Jun 30, 2024 | 53.74 Mn |
| Mar 31, 2024 | 41.61 Mn |
| Dec 31, 2023 | 84.78 Mn |
| Sep 30, 2023 | 44.96 Mn |
| Jun 30, 2023 | 34.74 Mn |
| Mar 31, 2023 | 33.70 Mn |
| Dec 31, 2022 | 29.59 Mn |
| Sep 30, 2022 | 33.78 Mn |
| Jun 30, 2022 | 35.43 Mn |
| Mar 31, 2022 | 30.98 Mn |
| Dec 31, 2021 | 29.74 Mn |
| Sep 30, 2021 | 58.02 Mn |